Core Viewpoint - The article discusses the introduction of Seladelpar, the first approved drug for treating Primary Biliary Cholangitis (PBC) in mainland China, highlighting its dual benefits in improving biochemical indicators and alleviating itching symptoms for patients [1][6]. Group 1: Disease Overview - Primary Biliary Cholangitis (PBC) is a rare, chronic autoimmune liver disease that disrupts the immune system, leading to bile duct damage and potential liver complications such as cirrhosis if untreated [3][4]. - The prevalence of PBC in China is reported at 20.5 per 100,000, which, while low compared to other liver diseases, is increasingly recognized due to improved diagnostic capabilities [3][4]. - Symptoms such as itching affect over 70% of PBC patients, significantly impacting their quality of life [3][5]. Group 2: Treatment Landscape - Historically, Ursodeoxycholic Acid (UDCA) has been the primary treatment for PBC, but 30%-40% of patients show inadequate response to this therapy [6][7]. - Seladelpar, a selective PPARδ agonist, represents a new treatment option that can significantly improve biochemical markers and reduce itching, addressing a long-standing challenge in PBC management [6][7][8]. Group 3: Patient Case and Implications - A case study of a patient, referred to as Xiao Liu, illustrates the common struggles faced by PBC patients, including delayed treatment due to a lack of awareness about the disease [7]. - The introduction of Seladelpar is seen as a significant advancement in the treatment of PBC, with clinical studies indicating its effectiveness and safety for Asian patients [8]. Group 4: Regulatory and Market Context - The issuance of the first Seladelpar prescription in China is facilitated by a temporary import policy for urgently needed rare disease medications, reflecting ongoing improvements in the rare disease drug assurance system [8]. - There is an expectation for Seladelpar to undergo formal approval processes in China, with hopes for inclusion in national health insurance to benefit a larger patient population [8].

Core Viewpoint - The introduction of the innovative drug Seladelpar for the treatment of primary biliary cholangitis (PBC) in China marks a significant advancement in treatment options for patients, enhancing the accessibility of rare disease medications in the country [1][2]. Group 1: Drug Introduction and Significance - Seladelpar is the first approved selective PPARδ agonist for treating PBC, suitable for adult patients who do not respond well to ursodeoxycholic acid (UDCA) or cannot tolerate it [1][3]. - The first prescription of Seladelpar was issued at Beijing Friendship Hospital, indicating a successful implementation of temporary import policies for urgently needed rare disease medications in China [1][2]. Group 2: Disease Overview and Patient Demographics - PBC is a rare, chronic autoimmune liver disease that has been included in China's second batch of rare disease listings, with a prevalence rate of 20.5 per 100,000, ranking second in Asia [2]. - The disease predominantly affects middle-aged women, with a male-to-female ratio of approximately 1:9, although the proportion of male patients has been increasing [2]. Group 3: Treatment Challenges and Needs - Traditional first-line treatment with UDCA fails to meet the needs of 30% to 40% of patients, who are at high risk of disease progression to liver cirrhosis or liver failure without effective second-line treatment [2]. - There is a clinical need for innovative therapies that can both delay disease progression and alleviate symptoms such as itching, which significantly impacts patients' quality of life [2]. Group 4: Benefits of Seladelpar - Seladelpar offers a breakthrough in PBC treatment by targeting various disease-related cells and processes, effectively improving bile accumulation, reducing liver inflammation and fibrosis, and alleviating itching symptoms [3]. - The drug is expected to provide dual benefits for patients, improving biochemical indicators and symptom relief, thus enhancing long-term prognosis and quality of life [3].

Core Viewpoint - The article highlights the prescription of Seladelpar, a drug for primary biliary cholangitis (PBC), as the first in mainland China, benefiting from a temporary import policy for rare disease medications in Beijing [1] Group 1: Drug Information - Seladelpar is a potent and selective PPARδ agonist that effectively improves cholestasis, reduces liver inflammation and fibrosis, and enhances symptoms and prognosis for PBC patients [1] - The drug is expected to be launched in the United States in August 2024 and in the European Union in February 2025 [1] Group 2: Policy Impact - The prescription of Seladelpar was made possible due to the policy advantages of the Tianzhu Rare Disease Guarantee Pilot Zone, allowing for rapid approval and access to cutting-edge treatments for PBC patients in need [1]

Core Viewpoint - Gilead's drug Seladelpar for primary biliary cholangitis (PBC) has been officially approved in the Boao Lecheng International Medical Tourism Pilot Zone, providing a new treatment option for PBC patients in China [1] Group 1: Drug Approval and Indications - Seladelpar is a potent selective peroxisome proliferator-activated receptor delta (PPARδ) agonist approved for the treatment of PBC [1] - The drug is indicated for adult patients with PBC who have an inadequate response to monotherapy with ursodeoxycholic acid (UDCA) or as a monotherapy for those who cannot tolerate UDCA [1] Group 2: Impact on Rare Disease Treatment - The approval of Seladelpar reflects China's ongoing efforts to enhance the accessibility of innovative drugs for rare diseases and to meet unmet clinical needs [1] - PBC has been included in China's "Second Batch of Rare Disease Catalog," highlighting the importance of addressing rare diseases in the healthcare system [1]

Core Insights - Seladelpar, a drug for primary biliary cholangitis (PBC), has been approved in Hainan Boao Lecheng International Medical Tourism Pilot Zone, marking it as the first potent selective PPARδ agonist approved for this condition globally [1][2] - PBC is an autoimmune liver disease that can lead to severe complications such as liver cirrhosis and liver failure if not treated effectively [1][2] - The approval of Seladelpar represents a significant advancement in treatment options for PBC patients, particularly those who do not respond well to the standard treatment with ursodeoxycholic acid (UDCA) [2] Industry Context - PBC has been included in China's second batch of rare disease catalog, with a reported prevalence of 20.5 per 100,000, predominantly affecting middle-aged women [2] - Approximately 40% of PBC patients do not respond adequately to UDCA, which poses a high risk of disease progression to decompensated cirrhosis and liver failure [2] - The introduction of Seladelpar is expected to address unmet clinical needs and improve both biochemical markers and symptoms such as itching, which affects 70% of patients [2] Regulatory Environment - The Boao Lecheng International Medical Tourism Pilot Zone is recognized as China's only "medical special zone," facilitating the introduction of innovative drugs and therapies [3] - Prior to its approval in Boao, Seladelpar was granted access through a clinical urgent import policy in August 2025, indicating a proactive approach to rare disease treatment in China [3]

Core Insights - Gilead showcased its commitment to health innovation at the China International Import Expo, presenting two significant products: the long-acting HIV pre-exposure prophylaxis drug Lenacapavir and the new drug for primary biliary cholangitis (PBC), Seladelpar [1][2][3] Product Highlights - Lenacapavir is a long-acting HIV capsid inhibitor that requires administration only twice a year, demonstrating over 99.9% efficacy in preventing HIV in global Phase III clinical trials [2] - Seladelpar is an innovative drug for PBC, a chronic autoimmune liver disease, which was approved in August 2023 and is the first therapy to improve biochemical markers and alleviate itching symptoms in PBC patients [3] Market Impact - Gilead has launched 13 innovative drugs in China, benefiting approximately 1.8 million patients, and aims to deepen its local strategy while enhancing drug accessibility and health equity [4] Collaborative Efforts - Gilead is actively pursuing collaborations to support the "Healthy China 2030" initiative, focusing on improving public health through academic exchanges, enhancing treatment capabilities in rural areas, and expanding innovative partnerships in oncology [6]

Core Insights - Gilead showcased two significant products at the China International Import Expo: the long-acting HIV pre-exposure prophylaxis drug Lenacapavir and the new drug for primary biliary cholangitis (PBC) Seladelpar, emphasizing its commitment to creating a healthier world [1][3] Product Highlights - Lenacapavir is a groundbreaking long-acting HIV capsid inhibitor that requires administration only twice a year, demonstrating over 99.9% efficacy in preventing HIV in global Phase III clinical trials [3][4] - Seladelpar is the first innovative therapy that improves biochemical markers and alleviates itching symptoms for PBC patients, which was included in the National Health Commission's list of rare diseases in 2023 [4] Market Entry and Approval - Lenacapavir received approval for HIV pre-exposure prophylaxis in Hainan Boao Lecheng International Medical Tourism Pilot Zone, almost simultaneously with FDA approval, marking a significant milestone for domestic drug approval processes [4] - Seladelpar was approved in Beijing under the urgent clinical need policy, providing new treatment hope for PBC patients in China [4] R&D Initiatives - Gilead is actively advancing local R&D with 16 ongoing projects in China, including 10 in oncology and 6 in non-oncology, aiming for synchronized global development to benefit Chinese patients [5] Access to Innovative Medicines - Over the past eight years, Gilead has launched 13 global innovative drugs in China, benefiting approximately 1.8 million patients, including notable products for HIV treatment and hepatitis [8] - The company emphasizes collaboration with various sectors to enhance access to innovative medicines and promote health equity [9]

Core Insights - Gilead Sciences' stock price dropped by 3.70% on November 7, attracting significant investor attention, despite the company's strong focus on innovation and development in the healthcare sector [1][2] - At the 8th China International Import Expo, Gilead showcased several innovative drugs, including the long-acting HIV pre-exposure prophylaxis drug Lenacapavir and the new drug Seladelpar for primary biliary cholangitis, highlighting its robust R&D capabilities [1] - Lenacapavir, as a first-in-class drug, requires only two doses per year and has demonstrated over 99.9% efficacy in global Phase III clinical trials, earning multiple international accolades [1] - Seladelpar is the first global innovative therapy that can simultaneously improve biochemical markers and alleviate pruritus symptoms in patients with primary biliary cholangitis, entering the Chinese market rapidly due to expedited drug review processes and favorable policies [1] Market Strategy - Gilead Sciences has made significant breakthroughs in introducing innovative drugs and actively integrates into the Chinese market through localized R&D strategies, conducting 16 clinical studies in China, many of which align with global timelines, particularly in oncology [2] - The company's commitment to the Chinese market is reflected in its plans to sign nearly ten collaborative projects to enhance the accessibility of innovative drugs and promote standardized treatment practices [2] - This proactive strategy not only boosts the company's market competitiveness but also contributes to the achievement of the "Healthy China 2030" goal [2] Long-term Outlook - Despite short-term stock price fluctuations causing market pressure, Gilead Sciences' ongoing innovation and strategic collaborations demonstrate long-term growth potential, instilling confidence in investors [2] - Investors are encouraged to monitor the company's movements in the Chinese market and its deep collaborations with partners to seize future investment opportunities [2] - Diversifying risks and maintaining a long-term perspective may be effective strategies for investing in such innovative companies [2]

Core Insights - Gilead Sciences showcased multiple products at the 8th China International Import Expo, including two Asia debut products: long-acting HIV pre-exposure prophylaxis drug Lenacapavir and a new drug for primary biliary cholangitis (PBC) named Seladelpar [1][2] Group 1: Lenacapavir - Lenacapavir is a globally first-of-its-kind long-acting HIV capsid inhibitor that requires administration only twice a year, demonstrating over 99.9% effectiveness in preventing HIV based on global Phase III clinical studies [1] - Lenacapavir has received several prestigious recognitions, including being ranked first in Science magazine's "Top 10 Scientific Breakthroughs of 2024" and being included in Time magazine's "Best Inventions of 2025" [1] - The drug was approved for HIV pre-exposure prophylaxis in Hainan Boao Lecheng International Medical Tourism Pilot Zone in late June, almost simultaneously with the approval from the U.S. FDA [1] Group 2: Seladelpar - Seladelpar is an innovative drug targeting patients with primary biliary cholangitis, a chronic autoimmune liver disease recognized as a "silent killer" and included in the National Health Commission's list of rare diseases in 2023 [2] - The drug is the first global therapy that can improve biochemical indicators in PBC patients while alleviating itching symptoms, which significantly impact the quality of life [2] - Seladelpar was approved in August under Beijing's clinical urgent import policy, marking a significant step in addressing the needs of PBC patients [2] Group 3: Gilead's Market Presence - Gilead Sciences has launched 13 global innovative drugs in China over the past eight years, benefiting approximately 1.8 million patients [2] - At the expo, Gilead plans to deepen collaborations with various parties to enhance the accessibility of innovative drugs and promote standardized diagnosis and treatment [2]

Core Insights - The China International Import Expo (CIIE) serves as a significant platform for global companies to showcase their innovations and engage with key decision-makers in the Chinese pharmaceutical market [1][2][3] - Gilead Sciences has experienced the benefits of the CIIE, particularly in accelerating the approval and market entry of innovative therapies in China [1][2][3] Policy and Regulatory Environment - China's continuous policy reforms in drug approval processes have created a favorable environment for innovative drugs, enhancing the attractiveness of the Chinese market for multinational pharmaceutical companies [1][2] - The establishment of expedited approval channels for breakthrough therapies and conditional approvals has significantly reduced the time for innovative drugs to enter the Chinese market [2][3] Market Dynamics and Opportunities - The CIIE has become a "policy windfall" and "information hub" for new drugs entering China, allowing companies to effectively communicate with regulatory bodies and enhance product recognition among healthcare professionals and patients [2][3] - Gilead's innovative drugs, such as Lenacapavir and Seladelpar, have demonstrated rapid approval and market entry following their showcases at the CIIE, highlighting the event's role in expediting access to new treatments [3][4][7] Collaboration and Local Partnerships - Gilead is actively pursuing collaborations with local pharmaceutical companies and healthcare platforms to strengthen its supply chain and enhance product accessibility in China [9][10] - The company is also focusing on educational initiatives to reduce stigma around diseases like HIV, thereby fostering a more informed patient population and improving market conditions [9][10] Future Directions - Gilead plans to continue its focus on both treatment and prevention in the HIV space, exploring innovative dosing regimens to improve patient adherence [8][9] - The company is engaged in multiple clinical studies globally, with a significant emphasis on advancing HIV treatment and prevention strategies [8][11] - Gilead's ongoing partnerships and collaborations with local innovators reflect a broader trend of multinational companies seeking to capitalize on China's growing pharmaceutical market [12]